



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_595_24

You asked:

I would be grateful if you could tell me how many patients were treated by individual drugs from the dermatology, gastroenterology, and rheumatology departments (for any disease) for the three-month period specified within the question.

I have provided a grid of drug names and department names requested in appendix A (below). Please fill in the grid with the numbers of patients (or forward in a format that best suits you) and include data for all hospitals in the organisation (question 1).

Thank you in advance.

Appendix A

Q1a – How many patients were treated with the following drugs from the following departments (for any disease) from the start of Jul 2024 to the end of Sept 2024?

Please use the latest available 3 months if Jul to Sept is not available and specify which 3 months has been used.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab			
Apremilast			
Bimekizumab			
Brodalumab			
Certolizumab Pegol			
Deucravacitinib			
Etanercept			
Guselkumab			
Infliximab (Remicade)			
Infliximab (Biosimilars)			
Ixekizumab			
Risankizumab			
Secukinumab			
Tildrakizumab			
Ustekinumab			
Upadacitinib			
Vedolizumab			
Filgotinib			
Golimumab			
Mirikizumab			
Ozanimod			

Etrasimod			
Tofacitinib			
Baricitinib			
Rituximab			
Sarilumab			
Tocilizumab			

Q1b – How many patients were treated with Ustekinumab and its biosimilars from the following departments (for any disease) from the start of Jul 2024 to the end of Sept 2024?

Please use the latest available 3 months if Jul to Sept is not available and specify which 3 months has been used.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Ustekinumab (Stelara)			
Ustekinumab (Pyzchiva)			
Ustekinumab (Uzpruvo)			
Ustekinumab (Wezenla)			

Our response:

Please find below as requested tables populated with the information Medicines Management are able to provide at this current time. The period the data relates to 1st July 24 to 30th September 24 as requested.

Please note - Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Q1a

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab	59	228	471
Apremilast	11		**
Baricitinib	5		39
Bimekizumab	17		11
Brodalumab	**		
Certolizumab Pegol	**		64
Deucravacitinib	14		
Etanercept			294

Etrasimod			
Filgotinib			8
Golimumab			58
Guselkumab	37		**
Infliximab (Biosimilars)	**	**	**
Infliximab (Remicade)	**	239	20
Ixekizumab	10		23
Mirikizumab			
Ozanimod		**	
Risankizumab	51	26	
Rituximab			32
Sarilumab			**
Secukinumab	8		98
Tildrakizumab	13		
Tocilizumab			83
Tofacitinib		**	9
Upadacitinib	13	22	22
Ustekinumab	36	182	16
Vedolizumab		189	

Q1b.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Ustekinumab (Stelara)	36	182	16
Ustekinumab (Pyzchiva)			
Ustekinumab (Uzpruvo)			
Ustekinumab (Wezenla)			